ReviewFrontiers in cardiovascular medicine2025
The mechanism of secreted frizzled-related protein 1 in alleviating cardiomyocyte injury and heart failure.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) is a clinical syndrome characterized by impairment of the heart's pumping function. Its core pathological basis is the vicious cycle of "injury reconstruction decompensation" triggered by cardiomyocyte damage. This review aims to systematically elucidate the molecular mechanism by which secreted frizzled-related protein 1 (Sfrp1; all proteins mentioned in the article are mouse genes, and Sfrp1 is used as the abbreviation) alleviates myocardial injury and delays the progression of HF through a multi-pathway interaction network. The main contents include (1) the core pathological mechanism of HF, such as oxidative stress (excessive ROS leads to calcium overload and mitochondrial apoptosis), autophagy disorder (the AngII/β5i axis inhibits protective autophagy), and abnormal apoptosis (imbalance of Bax/Bcl-2 triggers cardiomyocyte loss); (2) the structural features of Sfrp1, a secretory glycoprotein rich in cysteine domains (CRD), which inhibits the classical Wnt/β-catenin pathway by competitively binding to Wnt ligands; (3) the Sfrp1 six-layer protective mechanisms of Sfrp1: antagonizing the Wnt pathway to reduce ROS production and fibrosis; activating the Hippo/Notch pathways to inhibit pathological proliferation; promoting autophagy; downregulating Bax/Cyt c/Caspase-3; upregulating Bcl-2 to inhibit apoptosis; and improving calcium metabolism disorders by upregulating SERCA2a/MICU1. The conclusion suggests that coordinated regulation of these pathways by Sfrp1 interrupts the vicious cycle of HF. As a multi-target intervention molecule, Sfrp1 offers a novel approach to the targeted treatment of HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.